TrialJournal of Crohn's & colitis2026

Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.

Elisabeth De Greef et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.